The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated
Open accessAbstract
Background and Purpose— Warfarin is the most effective stroke prevention medication for high-risk individuals with atrial fibrillation, yet it is often underused. This study examined the magnitude of this problem in a large contemporary, prospective stroke registry. Methods— We analyzed data from the Registry of the Canadian Stroke Network, a prospective database of consecutive patients with stroke admitted to 12 designated stroke centers in Ontario (2003 to 2007). We included patients admitted with an acute ischemic stroke who (1) had a known history of atrial fibrillation; (2) were classified as high risk for systemic emboli according to published guidelines; and (3) had no known contraindications to anticoagulation. Primary end points were the use of prestroke antithrombotic medications and admission international normalized ratio. Results— Among patients admitted with a first ischemic stroke who had known atrial fibrillation (n=597), strokes were disabling in 60% and fatal in 20%. Preadmission medications were warfarin (40%), antiplatelet therapy (30%), and no antithrombotics (29%). Of those taking warfarin, three fourths had a subtherapeutic international normalized ratio (<2.0) at the time of stroke admission. Overall, only 10% of patients with acute stroke with known atrial fibrillation were therapeutically anticoagulated (international normalized ratio ≥2.0) at admission. In stroke patients with a history of atrial fibrillation and a previous transient ischemic attack or ischemic stroke (n=323), only 18% were taking warfarin with therapeutic international normalized ratio at the time of admission for stroke, 39% were taking warfarin with subtherapeutic international normalized ratio, and 15% were on no antithrombotic therapy. Conclusions— In high-risk patients with atrial fibrillation admitted with a stroke, and who were candidates for anticoagulation, most were either not taking warfarin or were subtherapeutic at the time of ischemic stroke. Many were on no antithrombotic therapy. These findings should encourage greater efforts to prescribe and monitor appropriate antithrombotic therapy to prevent stroke in individuals with atrial fibrillation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001) · JAMA · doi:10.1001/jama.285.18.2370 · Cited by 6,205
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
(1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420130036007 · Cited by 2,071
Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
Hylek, E. M., Go, A. S., Chang, Y., Jensvold, N. G., Henault, L. E., Selby, J. V., & Singer, D. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022913 · Cited by 1,277
Marini, C., De Santis, F., Sacco, S., Russo, T., Olivieri, L., Totaro, R., & Carolei, A. (2005) · Stroke · doi:10.1161/01.str.0000166053.83476.4a · Cited by 949 · cited 2×
“We included patients admitted with an acute ischemic stroke who (1) had a known history of atrial fibrillation; (2) were classified as high risk for systemic emboli according to published guidelines; and (3) had no known contraindications to anticoagulation.”
BackgroundMethodWhy Do Patients With Atrial Fibrillation Not Receive Warfarin?
Bungard, T. J., Ghali, W. A., Teo, K. K., McAlister, F. A., & Tsuyuki, R. T. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.1.41 · Cited by 593
Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK
Stewart, S., Murphy, N., Walker, A., McGuire, A., & McMurray, J. J. V. (2004) · Heart · doi:10.1136/hrt.2002.008748 · Cited by 590
Man-Son-Hing, M., Nichol, G., Lau, A., & Laupacis, A. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.7.677 · Cited by 538
Self-citationEffect of Study Setting on Anticoagulation Control
van Walraven, C., Jennings, A., Oake, N., Fergusson, D., & Forster, A. J. (2006) · Chest · doi:10.1378/chest.129.5.1155 · Cited by 487
Self-monitoring of oral anticoagulation: a systematic review and meta-analysis
Heneghan, C., Alonso-Coello, P., Garcia-Alamino, J., Perera, R., Meats, E., & Glasziou, P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68139-7 · Cited by 438
Waldo, A. L., Becker, R. C., Tapson, V. F., & Colgan, K. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.077 · Cited by 379
Beyth, R. J., Quinn, L., & Landefeld, C. S. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-9-200011070-00010 · Cited by 360
Antithrombotic Therapy in Atrial Fibrillation
Albers, G. W., Dalen, J. E., Laupacis, A., Manning, W. J., Petersen, P., & Singer, D. E. (2001) · Chest · doi:10.1378/chest.119.1_suppl.194s · Cited by 360
Self-citationWitt, D. M., Sadler, M. A., Shanahan, R. L., Mazzoli, G., & Tillman, D. J. (2005) · Chest · doi:10.1378/chest.127.5.1515 · Cited by 348
Gage, B. F., Boechler, M., Doggette, A. L., Fortune, G., Flaker, G. C., Rich, M. W., & Radford, M. J. (2000) · Stroke · doi:10.1161/01.str.31.4.822 · Cited by 302
Hylek, E. M., D’Antonio, J., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2006) · Stroke · doi:10.1161/01.str.0000209239.71702.ce · Cited by 250
Wilson, J.-A. S., Wells, P. S., Kovacs, M. J., Lewis, G. M., Martin, J. E., Burton, E., & Anderson, D. R. (2003) · Europe PMC (PubMed Central) · Cited by 197
Man-Son-Hing, M., & Laupacis, A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.13.1580 · Cited by 188
Self-citationChoudhry, N. K., Anderson, G. M., Laupacis, A., Ross-Degnan, D., Normand, S.-L. T., & Soumerai, S. B. (2006) · BMJ · doi:10.1136/bmj.38698.709572.55 · Cited by 186
Self-citationLip, G. Y. H., Kamath, S., Jafri, M., Mohammed, A., & Bareford, D. (2002) · Stroke · doi:10.1161/hs0102.101817 · Cited by 168
Status of Antithrombotic Therapy for Patients With Atrial Fibrillation in University Hospitals
Albers, G. W. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.20.2311 · Cited by 163
O'Donnell, M., Oczkowski, W., Fang, J., Kearon, C., Silva, J., Bradley, C., Guyatt, G., Gould, L., D'Uva, C., Kapral, M., et al. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70536-1 · Cited by 161
Self-citationDeplanque, D., Leys, D., Parnetti, L., Schmidt, R., Ferro, J. M., Reuck, J. D., Mas, J., Gallai, V., & the SAFE ll Investigators (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02086.x · Cited by 99
McAlister, F. A., Man-Son-Hing, M., Straus, S. E., Ghali, W. A., Anderson, D., Majumdar, S. R., Gibson, P., Cox, J. L., & Fradette, M. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050091 · Cited by 95
Choudhry, N. K., Soumerai, S. B., Normand, S. T., Ross‐Degnan, D., Laupacis, A., & Anderson, G. M. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.052 · Cited by 83
Self-citationvan Walraven, C., Oake, N., Wells, P. S., & Forster, A. J. (2007) · CHEST Journal · doi:10.1378/chest.06-2628 · Cited by 79
Partington, S. L., Abid, S., Teo, K. K., Oczkowski, W., & O'Donnell, M. J. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2006.12.019 · Cited by 68
Indredavik, B., Rohweder, G., & Lydersen, S. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01512.x · Cited by 67
Bell, C. M., Bajcar, J., Bierman, A. S., Li, P., Mamdani, M. M., & Urbach, D. R. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.22.2525 · Cited by 65
Paciaroni, M., Agnelli, G., Caso, V., Venti, M. P., Milia, P., Silvestrelli, G., Parnetti, L., & Biagini, S. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01344.x · Cited by 61
Bungard, T. J., Ghali, W. A., McAlister, F. A., et al. (2001) · PubMed · Cited by 56
The Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial Fibrillation
Ezekowitz, M. D., & Falk, R. H. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.904 · Cited by 49
Mant, J., Richards, S. H., Hobbs, R. F., Fitzmaurice, D. A., Lip, G. Y. H., Murray, E. T., Banting, M., Fletcher, K., Rahman, J. K., Allan, T. F., et al. (2003) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-3-9 · Cited by 49
Stroke prevention in atrial fibrillation: physicians’ attitudes to anticoagulation in older people
Vasishta, S., Toor, F., Johansen, A., & Hasan, M. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00184-4 · Cited by 41
Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review
Szucs, T. D., & Bramkamp, M. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01890.x · Cited by 32
Safety, Effectiveness, and Efficiency: A Web-Based Virtual Anticoagulation Clinic
Kelly, J. J., Sweigard, K., Shields, K., & Schneider, D. (2003) · The Joint Commission Journal on Quality and Safety · doi:10.1016/s1549-3741(03)29076-6 · Cited by 20
York, M., Agarwal, A. K., & Ezekowitz, M. D. (2003) · Journal of Thrombosis and Thrombolysis · doi:10.1023/b:thro.0000014590.83591.4c · Cited by 11
Cited by
Atrial fibrillation in patients with cryptogenic stroke
Gladstone, D. J., Spring, M., Dorian, P., Panzov, V., Thorpe, K. E., Hall, J., Vaid, H., O'Donnell, M., Laupacis, A., Côté, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311376 · Cited by 1,276
Self-citationAndrade, J., Khairy, P., Dobrev, D., & Nattel, S. (2014) · Circulation Research · doi:10.1161/circresaha.114.303211 · Cited by 1,187
The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
Singer, D. E., Chang, Y., Fang, M. C., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N., & Go, A. S. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-5-200909010-00003 · Cited by 656
Andrade, J. G., Aguilar, M., Atzema, C., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 562
Self-citationScreening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration
Freedman, B., Camm, J., Calkins, H., Healey, J. S., Rosenqvist, M., Wang, J., Albert, C. M., Anderson, C. S., Antoniou, S., Benjamin, E. J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.026693 · Cited by 537
Self-citation
Metadata
- Authors
- Gladstone, D. J., Bui, E., Fang, J., Laupacis, A., Lindsay, M. P., Tu, J. V., Silver, F. L., & Kapral, M. K.
- Venue
- Stroke
- Published
- 2009-01
- Volume
- 40
- Issue
- 1
- Pages
- 235-240
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2104343448
- Cited by
- 402
- References
- 39
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.